THIS INFORMATION IS INTENDED FOR US HEALTHCARE PROFESSIONALS
ABOUT CUMBERLAND  |  IMPORTANT SAFETY INFORMATION  |  FULL PRESCRIBING INFORMATION  |  NEWS
logo
register

Cumulative effective water clearance

The effect of Vaprisol on serum sodium was demonstrated in a double-blind, placebo-controlled, randomized, multicenter study in patients with euvolemic or hypervolemic hyponatremia (serum sodium 115-130 mEq/L), the primary efficacy endpoint of which was change from baseline in serum sodium during the course of treatment, measured by the baseline-adjusted area under the sodium-time curve (AUC) from the beginning through the end of treatment. Fluid restricted to ≤2.0 L/day in all patients. The mean baseline serum sodium concentrations in patients treated with Vaprisol or placebo were 123.3 mEq/L or 124.3 mEq/L, respectively.1,2

chart

Patients receiving Vaprisol 40 mg/day IV achieved a cumulative effective water clearance of more than 3.8 L by end of treatment (day 4) compared with 1.3 L for patients receiving placebo.1*

*Baseline-corrected.



REFERENCES: 1. Vaprisol Prescribing Information. Cumberland Pharmaceuticals Inc. 2. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447-457.